538-P: Copeptin and Renin Angiotensin Aldosterone System (RAAS) Activation in Long-Standing Type 1 Diabetes (T1D)
Petter Bjornstad(University of Colorado Denver), David Z.I. Cherney(University Health Network), Leif Erik Lovblom(Mount Sinai Hospital), Hillary A. Keenan(Joslin Diabetes Center), Pattara Wiromrat(University of Colorado Anschutz Medical Campus), Alanna Weisman(Mount Sinai Hospital), Leslie Cham(University Health Network), Vesta Lai(University Health Network), Yuliya Lytvyn(University Health Network), Andrej Orszag(University of Toronto), Vera Bril(University Health Network), Julie A. Lovshin(Sunnybrook Health Science Centre), Geneviève Boulet(University of Toronto), Linh T. Chung, Narinder Paul, Carissa Vinovskis(University of Colorado Denver), Bruce A. Perkins(Sinai Health System), JOSEPHINE M. TSE, Michael H. Brent(University of Toronto)
Cited by 0
Related Papers
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Residual Insulin Production and Pancreatic β-Cell Turnover After 50 Years of Diabetes: Joslin Medalist Study
|Diabetes|2010|497
Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction
|Nature Medicine|2017|493
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
|Circulation|2017|470